A live-attenuated tuberculosis (TB) vaccine candidate in development at Texas Biomedical Research Institute (Texas Biomed) elicits a much more balanced and effective immune response compared to the existing vaccine used across much of the world, according to preclinical research published in Nature Communications.
TB vaccine candidate provides complete and superior protection in primate study
